CRISIL Limited (NSE:CRISIL)
India
· Delayed Price · Currency is INR | Market Cap | 365.96B |
| Revenue (ttm) | 33.35B |
| Net Income (ttm) | 7.06B |
| Shares Out | 73.13M |
| EPS (ttm) | 96.57 |
| PE Ratio | 51.82 |
| Forward PE | 46.39 |
| Dividend | 56.00 (1.12%) |
| Ex-Dividend Date | May 7, 2025 |
| Volume | 62,915 |
| Average Volume | 104,901 |
| Open | 5,044.20 |
| Previous Close | 5,004.20 |
| Day's Range | 4,960.00 - 5,150.00 |
| 52-Week Range | 3,880.00 - 6,950.00 |
| Beta | -0.09 |
| RSI | 64.57 |
| Earnings Date | Apr 17, 2025 |
About CRISIL
CRISIL Limited, an analytical company, together with its subsidiaries, provides ratings, data, research, and analytics and solutions in India, Europe, North America, and internationally. It operates through two segment, Rating Services; and Research, Analytics, and Solutions. The company offers credit ratings for corporates, banks, and bank loans; credit analysis services; grading services; and analytical services. It also provides research and risk solutions, industry reports, customized research assignments, subscription to data services, ind... [Read more]
Financial Performance
In 2024, CRISIL's revenue was 32.60 billion, an increase of 3.83% compared to the previous year's 31.40 billion. Earnings were 6.84 billion, an increase of 3.89%.
Financial StatementsNews
CRISIL Q4 FY25 Results: Net profit rises 16% YoY to ₹159.8 crore, Margin expands to 28.5%
CRISIL Ltd has reported a strong set of numbers for the quarter ended March 31, 2025, with net profit rising 16% year-on-year to ₹159.8 crore, compared to ₹137.7 crore in the same period last year. Th...
Crisil shares drop over 8% as Q3 revenue declines
Crisil Limited, a subsidiary of S&P Global, faced a sharp decline in its stock price, dropping over 8% after reporting a slight dip in Q3 FY25 revenue. Despite strong profitability growth, investor se...
Crisil Q3 Results: Revenue down 0.5% to Rs 912.91 crore, Net Profit up 7.03% YoY
Crisil Limited, a subsidiary of S&P Global, has announced its audited financial results for Q3 FY25, reflecting a mixed performance across its revenue and profitability metrics. Key Financial Highligh...
Top gainers today: Piramal Pharma surges 5.85%, CRISIL rises 3.63%, Aditya Birla Capital gains 2.76%, AstraZeneca Pharma up 2.57%
At 12:53 PM, the stock market witnessed notable gains across several stocks. Here’s a look at the top performers: Piramal Pharma Limited (PPL Pharma): The stock climbed 5.85%, trading at ₹234.20. CRIS...
CRISIL invests Rs 33.25 Crore in online PSB Loans
CRISIL Limited has announced an investment of ₹33.25 crore to acquire a 4.08% post-money, fully diluted stake in Online PSB Loans Limited (OPL). This strategic move was approved during a board meeting...
Stock to Watch: CRISIL reports strong Q3 CY24 performance with 10.3% revenue growth and robust profit
CRISIL Limited has reported impressive financial results for Q3 CY24, with consolidated revenue increasing by 10.3% year-on-year to ₹811.8 crore, driven by strong performance in ratings services and r...
CRISIL Declares Interim Dividend of Rs 15 Per Share for Q3 CY24
CRISIL Limited has announced an interim dividend of ₹15 per share for the third quarter of CY24, reflecting its strong financial performance and commitment to shareholder returns. This dividend marks ...
CRISIL announces merger with subsidiary Bridge to India Energy
CRISIL Limited has approved a scheme of amalgamation to merge its wholly owned subsidiary, Bridge to India Energy Private Limited, with itself. The merger aims to achieve operational synergies, effect...
CRISIL Q2 FY25: Revenue up 1.8% QoQ to ₹811.84 crore, Net Profit at ₹171.55 crore
CRISIL Limited reported strong financial performance in the second quarter of FY25, with revenue and profitability seeing solid growth. Below are the key highlights from the company’s consolidated res...